Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of SCANCELL S
No Price
Closing Price XLON 01.05.2026:
15,50 GBX
01.05.2026 15:14
Current Prices from SCANCELL S
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
London
SCLP.L
GBX
01.05.2026 15:14
15,50 GBX
1,50 GBX
+10,71 %
UTC
SCNLF
USD
30.04.2026 20:00
0,17 USD
0,00 USD
Share Float & Liquidity
Free Float96,25 %
Shares Float998,86 M
Shares Outstanding1,04 B
Company Profile for SCANCELL S Share
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
